Google NewsClarity Pharmaceuticals (ASX:CU6) Plunges as Clinical-Stage Biotech Sell-Off Continues - Kalkine
Clarity Pharmaceuticals (ASX:CU6) Plunges as Clinical-Stage Biotech Sell-Off Continues Kalkine
CLARITY PHARMA ORDINARY (CU6) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXClarity Pharmaceuticals (CU6 ASX: CU6) Rises 9% as Traders Rotate Into Biotech Stocks - Kalkine
Clarity Pharmaceuticals (CU6 ASX: CU6) Rises 9% as Traders Rotate Into Biotech Stocks Kalkine
Clarity receives $9.8 million R&D tax incentive refund
other announcement
KalkineInsider Move Sparks Buzz Around Clarity Pharma Update
Highlights Insider transaction draws market attention Strong internal ownership remains intact Broader market trends add context The Australian equities landscape continues to evolve as insider activity offers subtle cues about company direction and sentiment within the ASX stock market. A recent development involving Clarity Pharmaceuticals Limited (CU6) has drawn interest across market watchers, particularly as leadership-level transactions often carry deeper implications. While such moves ...
Change of Director's Interest Notice - Parker
director_dealing announcement
Motley FoolWhy Clarity Pharmaceuticals shares just fell 5% on today's announcement
Investors are balancing Clarity's long-term potential against near-term uncertainty. The post Why Clarity Pharmaceuticals shares just fell 5% on today's announcement appeared first on The Motley Fool Australia.
Why Clarity Pharmaceuticals shares just fell 5% on today’s announcement - The Motley Fool Australia
Why Clarity Pharmaceuticals shares just fell 5% on today’s announcement The Motley Fool Australia
Clarity signs a Commercial Manufacturing Agreement
other announcement
Co-PSMA data published in the European Urology journal
other announcement
Clarity signs a large-scale Manufacturing Supply Agreement
other announcement
Clarity Pharma (ASX:CU6) AMPLIFY Trial Consent Completed, ASX 300 Watch
Highlights Radiopharmaceutical developer reported completion of participant consent for a pivotal clinical trial. Diagnostic imaging agent designed for prostate cancer detection forms the centre of ongoing clinical research. Trial activity across Australia and the United States highlights expanding interest in theranostic medicine. Clarity Pharmaceuticals activity within the ASX 300 reflects progress in radiopharmaceutical research as a prostate cancer imaging trial advances through clinical ...
Why Clarity Pharmaceuticals (ASX:CU6) Is Up 7.0% After AMPLIFY Trial Consent Completion And What's Next - simplywall.st
Why Clarity Pharmaceuticals (ASX:CU6) Is Up 7.0% After AMPLIFY Trial Consent Completion And What's Next simplywall.st
Clarity Pharma Trial Momentum Draws Market Attention
Highlights AMPLIFY trial recruitment expands beyond initial expectations Radiopharmaceutical research continues to attract global attention Market focus shifts to pipeline progress and long-term outlook Clarity Pharmaceuticals gains attention after strong recruitment progress in its AMPLIFY clinical trial. The development highlights growing interest in radiopharmaceutical research and the company’s advancing pipeline in prostate cancer imaging. Debate over the valuation of Clarity...
AMPLIFY trial - Target number of participants achieved
other announcement
SECuRE trial to continue with no modifications to protocol
other announcement
Co-PSMA abstract accepted for oral presentation at EAU
other announcement
Positive guidance from the US FDA on Cu-64 SARTATE Phase III
guidance announcement
Clarity to present DISCO trial data at ASCO-GI 2026
other announcement
Change of Director's Interest Notice - M Parker
director_dealing announcement
Change of Director's Interest Notice - C Biggin
director_dealing announcement
Change of Director's Interest Notice - A Taylor
director_dealing announcement